Hormonal
SGLT-2 inhibitors reduce body weight (0.9-2.5 kg) and improve cardiovascular and renal outcomes in patients with diabesity by inducing glycosuria, making them a valuable class of medication for managing both metabolic and organ-specific risks.
SGLT-2 inhibitors (like Jardiance or Farxiga) are oral diabetes medications that also help with modest weight loss (1-2.5 kg) and protect your heart and kidneys. They work by removing excess sugar through urine. While this can increase the risk of yeast infections or UTIs, good hygiene and doctor guidance can manage this. They are particularly beneficial if you have heart or kidney risks associated with your diabetes.
They have been associated with a reduction in HbA1c of about 0.69% and a weight loss between 0.9-2.5 kg... significant cardiovascular benefits in both groups of patients... overall reduced risk by 35% [renal mortality and morbidity].
Why this rating
Based on meta-analyses and landmark trials cited in the review.
Source
Management of diabesity: Current concepts
Maria Michaelidou et al. · World Journal of Diabetes · 2023
DOI 10.4239/wjd.v14.i4.396
More from this paper
- High-dose GLP-1 receptor agonists (specifically semaglutide 2.4 mg) combined with lifestyle interventions produce significant, sustainable weight loss (-14.9% body weight) and improved glycemic control in patients with diabesity, making them superior to insulin and other antidiabetic agents regarding weight management.Good
- Weight loss of 15 kg can induce remission of Type 2 Diabetes in approximately 70% of individuals, and even smaller weight losses (5 kg) improve insulin sensitivity and glycemic control, highlighting the primacy of lifestyle interventions in diabesity management.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →